6-azidomethyl-2-chloro-3-cyanopyridine | 267413-16-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-azidomethyl-2-chloro-3-cyanopyridine
• 英文别名: 6-(azidomethyl)-2-chloropyridine-3-carbonitrile
• CAS: 267413-16-1
• 化学式: C₇H₄ClN₅
• 分子量: 193.595
• InChiKey: WTDJOUOEGIUTFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  51
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-azidomethyl-2-chloro-3-cyanopyridine 在 水 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 15.0h， 生成 6-Aminomethyl-2-chloro-nicotinonitrile
  参考文献：
  名称：

  Non-covalent thrombin inhibitors featuring P3-Heterocycles with P1-Bicyclic arginine surrogates

  摘要：

  Novel, potent, and highly selective classes of thrombin inhibitors were identified, which resulted from judicious combination of P-4-aromatics and P-2-P-3-heterocyclic dipeptide surrogates with weakly basic (calcd pK(a) similar tonon-basic-8.6) bicyclic P-1-arginine mimics. The design, synthesis, and biological activity of achiral, non-covalent, orally bioavailable inhibitors NC1-NC44 featuring P-1-indazoles, benzimidazoles, indoles, benzotriazoles, and aminobenzisoxazoles is disclosed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00585-1
• 作为产物：
  描述：

  2-氯-6-甲基-3-吡啶甲腈 在 N-溴代丁二酰亚胺(NBS) 、 sodium azide 、 过氧化苯甲酰 作用下， 以 四氯化碳 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 6-azidomethyl-2-chloro-3-cyanopyridine
  参考文献：
  名称：

  Non-covalent thrombin inhibitors featuring P3-Heterocycles with P1-Bicyclic arginine surrogates

  摘要：

  Novel, potent, and highly selective classes of thrombin inhibitors were identified, which resulted from judicious combination of P-4-aromatics and P-2-P-3-heterocyclic dipeptide surrogates with weakly basic (calcd pK(a) similar tonon-basic-8.6) bicyclic P-1-arginine mimics. The design, synthesis, and biological activity of achiral, non-covalent, orally bioavailable inhibitors NC1-NC44 featuring P-1-indazoles, benzimidazoles, indoles, benzotriazoles, and aminobenzisoxazoles is disclosed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00585-1

文献信息

• Thrombin inhibitors
  申请人：Merck & Co., Inc.

  公开号：US06376499B1

  公开（公告）日：2002-04-23

  Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is N Y1 or O; c is CY2 or N; d is CY2; e is CY1 or N; f is CY1 or N; g is CY1 or N; Y1 is hydrogen, C1-4 alkyl, or halogen; Y2 is hydrogen, C1-4 alkyl, C3-7 cycloalkyl, halogen, NH2, OH or C1-4 alkoxy; A is  and W, X, Z, R3, R4 and R5 are defined in the specification.

  本发明的化合物在抑制凝血酶和相关的血栓闭塞方面具有以下结构：或其药用盐，其中b为N、Y1或O；c为CY2或N；d为CY2；e为CY1或N；f为CY1或N；g为CY1或N；Y1为氢、C1-4烷基或卤素；Y2为氢、C1-4烷基、C3-7环烷基、卤素、NH2、OH或C1-4烷氧基；A为，W、X、Z、R3、R4和R5在说明书中有定义。
• THROMBIN INHIBITORS
  申请人：Merck & Co., Inc.

  公开号：EP1124823A1

  公开（公告）日：2001-08-22
• US6376499B1
  申请人：——

  公开号：US6376499B1

  公开（公告）日：2002-04-23
• [EN] THROMBIN INHIBITORS<br/>[FR] INHIBITEURS DE LA THROMBINE
  申请人：MERCK & CO INC

  公开号：WO2000026210A1

  公开（公告）日：2000-05-11

  Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having structure (I) or a pharmaceutically acceptable salt thereof, wherein b is NY1 or O; c is CY2 or N; d is CY2; e is CY1 or N; f is CY1 or N; g is CY1 or N; Y1 is hydrogen, C¿1-4? alkyl, or halogen; Y?2¿ is hydrogen, C¿1-4? alkyl, C3-7 cycloalkyl, halogen, NH2, OH or C1-4 alkoxy; A is (II), (III), (IV) or (V); and W, X, Z, R?3, R4 and R5¿ are defined in the specification.
• Non-covalent thrombin inhibitors featuring P3-Heterocycles with P1-Bicyclic arginine surrogates
  作者：Jingrong Jean Cui、Gian-Luca Araldi、John E Reiner、Komandla Malla Reddy、Scott J Kemp、Jonathan Z Ho、Daniel V Siev、Lala Mamedova、Tony S Gibson、John A Gaudette、Nathaniel K Minami、Susanne M Anderson、Annette E Bradbury、Thomas G Nolan、J.Edward Semple

  DOI：10.1016/s0960-894x(02)00585-1

  日期：2002.10

  Novel, potent, and highly selective classes of thrombin inhibitors were identified, which resulted from judicious combination of P-4-aromatics and P-2-P-3-heterocyclic dipeptide surrogates with weakly basic (calcd pK(a) similar tonon-basic-8.6) bicyclic P-1-arginine mimics. The design, synthesis, and biological activity of achiral, non-covalent, orally bioavailable inhibitors NC1-NC44 featuring P-1-indazoles, benzimidazoles, indoles, benzotriazoles, and aminobenzisoxazoles is disclosed. (C) 2002 Elsevier Science Ltd. All rights reserved.